ASCENT-04 / KEYNOTE-D19
Showed that pairing an ADC with immunotherapy beats chemotherapy plus immunotherapy in first-line PD-L1-positive TNBC.
PFS 11.2 vs 7.8 months (HR 0.65); ASCO 2026 update showed improved PFS2. Approved 2026. Establishes ADC + checkpoint inhibitor as the new first-line standard for PD-L1+ disease.
- Median 11.2 vs 7.8 months with Sacituzumab govitecan + pembrolizumab compared with Chemotherapy + pembrolizumab; about 3.4 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 35 percent lower chance of the event at any given time (hazard ratio 0.65, likely range 0.51 to 0.84).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 60 vs 53 out of 100 had their tumour shrink with Sacituzumab govitecan + pembrolizumab compared with Chemotherapy + pembrolizumab; 7 more per 100.
- Roughly one extra person helped for every 14 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- Numbers are not recorded here for this endpoint. Sacituzumab govitecan + pembrolizumab: Immature; PFS2 favoured the ADC arm in the ASCO 2026 update.; Chemotherapy + pembrolizumab.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Immature; PFS2 favoured the ADC arm in the ASCO 2026 update.
- These results apply to the people the trial enrolled: First-line PD-L1+ (CPS ≥10) metastatic TNBC: sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (PD-L1); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
443 participants enrolled.
Immature; PFS2 favoured the ADC arm in the ASCO 2026 update.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Sacituzumab govitecan + pembrolizumab | 221 | 11.2 months | 0.65 (0.51–0.84) | 0.0009 | link |
| Chemotherapy + pembrolizumab | 222 | 7.8 months | ||||
| Objective response rate | Sacituzumab govitecan + pembrolizumab | — | 60% | — | — | — |
| Chemotherapy + pembrolizumab | — | 53% | ||||
| Overall survival | Sacituzumab govitecan + pembrolizumab | — | Immature; PFS2 favoured the ADC arm in the ASCO 2026 update. | — | — | — |
| Chemotherapy + pembrolizumab | — | — |
Pages like this
not linked directly; found by shared links- TrialASCENT-03
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan.
- TrialASCENT
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan.
- TrialTROPION-Breast05
Shares ADC + checkpoint inhibitor, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Pembrolizumab.
- IdeaNeoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC
Shares ADC + checkpoint inhibitor, Sacituzumab govitecan, Pembrolizumab, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast02
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Triple-negative breast cancer (TNBC).
- IdeaADC for residual disease after KEYNOTE-522
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Sacituzumab govitecan, Pembrolizumab.
- TrialKEYNOTE-355
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Pembrolizumab, Triple-negative breast cancer (TNBC).
- TechnologyDual-payload ADC
Shares TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Triple-negative breast cancer (TNBC).